143 related articles for article (PubMed ID: 2979063)
1. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
Bumol TF; Baker AL; Andrews EL; DeHerdt SV; Briggs SL; Spearman ME; Apelgren LD
Targeted Diagn Ther; 1988; 1():55-79. PubMed ID: 2979063
[No Abstract] [Full Text] [Related]
2. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
Apelgren LD; Zimmerman DL; Briggs SL; Bumol TF
Cancer Res; 1990 Jun; 50(12):3540-4. PubMed ID: 2340502
[TBL] [Abstract][Full Text] [Related]
3. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
[TBL] [Abstract][Full Text] [Related]
4. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.
Starling JJ; Maciak RS; Hinson NA; Hoskins J; Laguzza BC; Gadski RA; Strnad J; Rittmann-Grauer L; DeHerdt SV; Bumol TF
Cancer Res; 1990 Dec; 50(23):7634-40. PubMed ID: 1979247
[TBL] [Abstract][Full Text] [Related]
5. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.
Spearman ME; Goodwin RM; Kau D
Drug Metab Dispos; 1987; 15(5):640-7. PubMed ID: 2891480
[TBL] [Abstract][Full Text] [Related]
6. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
Johnson DA; Laguzza BC
Cancer Res; 1987 Jun; 47(12):3118-22. PubMed ID: 3495327
[TBL] [Abstract][Full Text] [Related]
7. The use of anthracycline-antibody complexes for specific antitumor activity.
Pietersz GA; Smyth MJ; Farquhar I; McKenzie C
Targeted Diagn Ther; 1988; 1():25-53. PubMed ID: 2979059
[No Abstract] [Full Text] [Related]
8. Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.
Apelgren LD; Bailey DL; Briggs SL; Barton RL; Guttman-Carlisle D; Koppel GA; Nichols CL; Scott WL; Lindstrom TD; Baker AL
Bioconjug Chem; 1993; 4(2):121-6. PubMed ID: 7873643
[TBL] [Abstract][Full Text] [Related]
9. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
Laguzza BC; Nichols CL; Briggs SL; Cullinan GJ; Johnson DA; Starling JJ; Baker AL; Bumol TF; Corvalan JR
J Med Chem; 1989 Mar; 32(3):548-55. PubMed ID: 2783975
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.
Smyth MJ; Pietersz GA; Farquhar I; McKenzie C
Targeted Diagn Ther; 1988; 1():123-56. PubMed ID: 2979055
[No Abstract] [Full Text] [Related]
11. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
Johnson DA; Baker AL; Laguzza BC; Fix DV; Gutowski MC
Cancer Res; 1990 Mar; 50(6):1790-4. PubMed ID: 2306731
[TBL] [Abstract][Full Text] [Related]
12. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
Ono M; Tanaka N
In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
[TBL] [Abstract][Full Text] [Related]
13. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxin therapy of malignancy.
Grossbard ML; Nadler LM
Important Adv Oncol; 1992; ():111-35. PubMed ID: 1582669
[No Abstract] [Full Text] [Related]
15. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.
Petersen BH; DeHerdt SV; Schneck DW; Bumol TF
Cancer Res; 1991 May; 51(9):2286-90. PubMed ID: 2015593
[TBL] [Abstract][Full Text] [Related]
16. Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB.
Riggin A; Clodfelter D; Maloney A; Rickard E; Massey E
Pharm Res; 1991 Oct; 8(10):1264-9. PubMed ID: 1796044
[TBL] [Abstract][Full Text] [Related]
17. Tumour therapy with Vinca alkaloids targeted by a hybrid-hybrid monoclonal antibody recognising both CEA and Vinca alkaloids.
Corvalan JR; Smith W; Gore VA
Int J Cancer Suppl; 1988; 2():22-5. PubMed ID: 3162442
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
[TBL] [Abstract][Full Text] [Related]
19. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
20. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas.
Schneck D; Butler F; Dugan W; Littrell D; Petersen B; Bowsher R; DeLong A; Dorrbecker S
Clin Pharmacol Ther; 1990 Jan; 47(1):36-41. PubMed ID: 2295217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
